para-aminosalicylic acid


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.
Related to para-aminosalicylic acid: Sodium aminosalicylate

p-aminosalicylic acid

 (PAS) (PASA) [ah-me″no-sal-ĭ-sil´ik]
an analogue of p-aminobenzoic acid that inhibits folic acid synthesis in Mycobacterium tuberculosis, used in the treatment of tuberculosis, administered orally. In pharmacy it is officially called aminosalicylic acid. It enhances the potency of streptomycin and delays the development of bacilli resistant to streptomycin. Gastrointestinal irritation accompanied by anorexia, nausea, and vomiting may be reduced by administering the drug with food at mealtime.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

para-aminosalicylic acid

(păr′ə-ə-mē′nō-săl′ĭ-sĭl′ĭk, ăm′ə-nō-)
n. Abbr. PAS
A bacteriostatic agent, C7H7NO3, prescribed for the treatment of tuberculosis. Also called aminosalicylic acid.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

para-aminosalicylic acid (PAS)

A drug formerly widely used to treat pulmonary TUBERCULOSIS but now superceded by more effective antibiotics. The drug is on the WHO official list.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Vander Heyden et al., "Quantitative determination of para-aminosalicylic acid and its degradation product meta-aminophenol in pellets by ionpair high-performance liquid chromatography applying the monolithic Chromolith Speedrod RP-18e column," Biomedical Chromatography, vol.
Zeng, "HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues," Journal of Pharmaceutical and Biomedical Analysis, vol.
The intrinsic reproducibility of phenotypic DST for several drugs tested routinely including ethambutol, thioamides, cycloserine, and para-aminosalicylic acid is poor.
Acquired resistance to capreomycin was significantly associated with receiving the following drugs or drug groups: <3 effective drugs (p = 0.008), an ineffective fluoroquinolone (p = 0.009), or ineffective para-aminosalicylic acid (p = 0.02).
Routine DST for pyrazinamide, kanamycin, cycloserine, and para-aminosalicylic acid was not performed.
Fluoroquinolones had the highest rate of resistance (16.4%), followed by capreomycin (5.7%), para-aminosalicylic acid (3.7%), and amikacin (3.2%).
A regimen with rifabutin, ciprofloxacin, amikacin, para-aminosalicylic acid, and clofazimine led to a short phase of negative sputum cultures, but a chest X-ray showed no improvement.
We identified all dispensings of isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin, ethionamide, kanamycin, cycloserine, capreomycin, and para-aminosalicylic acid (PAS).